All
Incyte and CMS Collaborate to Develop Povorcitinib in Numerous Chinese Regions
Povorcitinib is being evaluated for non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma, and chronic spontaneous urticaria.
Artificial Intelligence Mode Demonstrates Accuracy in the Prediction of Skin Cancer Risk Using 2D Images
An XAI AI model using 2D facial images accurately predicted skin cancer better than traditional factors, according to a study advocating for AI-driven screening.
J-Code for Ycanth Officially Launches Today
The permanent J-code for the molluscum contagiosum treatment is now live.
Sexually Dimorphic Inflammatory Responses Key to Understanding Vitiligo, Study Finds
The study uncovered sexual dimorphism in melanocyte stem cell migration rates due to UVB-induced inflammatory responses in mice.
Dermatology Conferences and Meetings Calendar 2024: April
Dermatology Times asked our readers to share what conferences they are looking forward to in the second quarter of 2024.
Derm In The News: March 24-30
Keep up with the latest headlines in dermatology from the past week, including the discovery of a gene mutation that may cause psoriasis, the role of skin biopsies in detecting Parkinson's disease, and more.
The Weekly Roundup: March 25-29
ICYMI, this week we had news about bringing awareness to ethics in aesthetics, the 7 year anniversary of dupilumab's approval for atopic dermatitis, and more.
Discovering Dermatology Times: March 2024 Print
Learn more about the in-depth topics covered in the March 2024 print issue of Dermatology Times.
EltaMD Rings Bell at New York Stock Exchange as Continued Celebration of National Dermatologist Day
EltaMD representatives and dermatologists partook in the celebration on March 28 as a continuation of the celebration and momentum of the newly-established National Dermatologist Day.
Dermatology Times March 2024 Recap
Dermatology Times is looking back on the top stories in dermatology from the month of March.
Interview Intersection: Expert Interviews From March 2024
Dermatology Times is recapping our top expert interviews from the month of March.
Hidradenitis Suppurativa in Transgender and Gender-Diverse Patients and Hormone Therapy
Researchers found that patients who initiated gender-affirming hormone therapy with testosterone were more likely to experience a worsening of their HS symptoms.
Discovering Dermatology Times: March 2024 Enhancing Psoriasis Management Supplement
Learn more about the in-depth topics covered in the March 2024 enhancing psoriasis management supplement of Dermatology Times.
Radiation Therapy Associated With Elevated Skin Cancer Risk in Patients With Breast Cancer
Skin Swab Analysis Reveals Early Predictors of Atopic Dermatitis in Infants
Researchers shared details of a noninvasive technique that detects abnormal inflammatory cytokine profiles in the skin of asymptomatic infant patients who subsequently develop AD.
Dupilumab for Atopic Dermatitis: 7 Years Later
Today officially marks 7 years since the US FDA approved dupilumab for the treatment of atopic dermatitis. Here's a look back at its approval timeline and all it has accomplished in the dermatology world in the time since.
Reviewing Late-Breaking Research From AAD 2024
Catch up on late-breaking research shared at the 2024 American Academy of Dermatology Annual Meeting.
A Spotlight on SCIN: A New Tool From Google and Researchers at Stanford Medicine
Researchers from Google and Stanford Medicine recently partnered to develop the Skin Condition Image Network dataset, a tool aimed at providing image resources for conditions across skin tones.
Amy Spizuoco, DO, FAOCD: Addressing STDs and Utilizing Dermatopathology With Care in Diverse Patient Populations
Spizuoco shares pearls from her sessions, "Infectious Diseases: The Story Behind STDs," and "Everything You Need to Know About Dermatopathology and the Dermatopathologist," from the Diversity in Dermatology conference.
Pointers With Portela: Providing Free Dermatologic Care
In this week’s Pointers With Portela, the 208SkinDoc reveals his journey toward providing free dermatologic care through a mobile clinic.
Melanoma and the Wrong Site
In this month's Legal Eagle column, learn about the liabilities and how to prevent wrong-site procedures.
Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy
China’s NMPA has approved tunlametinib for the treatment of patients with NRAS-mutated advanced melanoma after prior anti–PD-1/PD-L1 therapy.
Allergan Aesthetics Launches New Book to Bring More Awareness to Ethics in Aesthetics
Moving the Needle on Ethics includes articles and interviews featuring experts in aesthetics.
Experts Develop Benefit-Risk Conceptual Framework for Biologic Use in Pregnancy
This framework considers both the pregnant patient who is taking the medication and the fetus who may be exposed to it while in the womb. It assesses potential benefits and risks for both parties.
Match Day 2024: A Look at Statistics on the Dermatology Match
We compare 2024 Match Day statistics with data from recent years.
In Psoriatic Arthritis, Psychosocial Factors Significantly Increase Risk of Joint Pain
Up to one quarter of patients with PsA experience persistent joint pain. In a recent study, higher levels of fatigue, depression, and anxiety were associated with joint pain.
Habits, Cultural Norms, and Rapid Advances In Technology Have Dramatically Changed the Aesthetic Medicine Landscape
Amy B. Lewis, MD, explores the evolution of aesthetic dermatology, delving into injection sophistication, devices, and top procedures.
POLL: Would You Consider Utilizing Virtual Reality in Your Practice or to Further Your Education?
Click here to answer today's poll and read more about recent uses of VR in dermatology education and practice.
Study Reveals Somatic and Habitual Predisposing Factors Topographically-Related to Body-Focused Repetitive Behaviors
Positive feelings accompanying BFRBs such as dermatillomania or trichotillomania may act as an important maintenance factor, researchers wrote.
Current Treatment Options for Cutaneous Lupus Erythematosus Are 'Notably Inadequate,' Review Says
Researchers analyzed the current treatment and research landscape for CLE in a review published in the Journal of Dermatology.